Fresenius Kabi Oncology

• Fresenius Kabi plunges 19% ahead of SAT hearing on delisting

  At the NSE, the stock tumbled 18.64 per cent to Rs 119.10. Fresenius Kabi Oncology has again approached SAT against Sebi which recently gave a conditional nod to the company to delist from the Indian stock market.

• Tribunal to hear Fresenius Kabi appeal against Sebi on Jun 24

  The Securities Appellate Tribunal (SAT) will hear on June 24 healthcare firm Fresenius Kabi Oncology's appeal against an order by the Securities and Exchange Board of India (Sebi) related to non-compliance with 25 per cent minimum public shareholding norms.

• Fresenius Kabi challenges Sebi's minimum public holding order

  Healthcare firm Fresenius Kabi Oncology approached the Securities Appellate Tribunal (SAT) on Wednesday against market regulator Securities and Exchange Board of Indias order on minimum 25 per cent public shareholding and sought permission to delist its shares from the stock exchanges.

• Action-packed weeks ahead for shares of multinational companies: Analysts

  Shares of multi-national companies (MNCs) will be in focus in the next few weeks as many of them will be required to either reduce promoter shareholding to a regulatory cap of 75 per cent or get delisted.

• Fresenius Kabi Oncology Ltd - Disinvestment of entire shareholding in subsidiary company

  With reference to earlier announcement dated May 27, 2011 regarding disinvestment of Fresenius Kabi Oncology Ltd's entire shareholding in Fresenius Kabi Oncology Plc, UK to Fresenius Kabi, Germany and its affiliates, Fresenius Kabi Oncology Ltd has now informed BSE that the Company has finalized and executed the share purchase agreement with Fr...

• Fresenius Kabi Oncology Ltd - Fixes Book Closure for AGM

  Fresenius Kabi Oncology Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from August 01, 2011 to August 11, 2011 (both days inclusive) for the purpose of Annual General Meeting (AGM) of the Company to be held on August 11, 2011.

• Fresenius Kabi Oncology Ltd - Outcome of Board Meeting

  Fresenius Kabi Oncology Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 26, 2011, inter alia, has: 1. Not recommended any dividend for the year. 2. Recommended the re-appointment of Dr. Michael Schonhofen as a Director liable to retire by rotation. 3. Recommended the re-appointment of Mr. Nitin Potdar as a...

• Fresenius Kabi Oncology reports net profit of Rs 80.23 crore in the year ended March 2010

  Sales rise 59.80% to Rs 412.20 croreFresenius Kabi Oncology reported net profit of Rs 80.23 crore in the year ended March 2010 as against net loss of Rs 77.69 crore during the previous year ended March 2009. Sales rose 59.80% to Rs 412.20 crore in the year ended March 2010 as against Rs 257.94 crore during the previous year ended March 2009.

• Fresenius Kabi Oncology appoints director

  With effect from 20 January 2010 The board of Fresenius Kabi Oncology in its meeting on 20 January 2010 has appointed Mats Christer Henriksson as director of the company with effect from 20 January 2010.

• Fresenius Kabi Oncology appoints director

  With effect from 20 January 2010 The board of Fresenius Kabi Oncology in its meeting on 20 January 2010 has appointed Mats Christer Henriksson as director of the company with effect from 20 January 2010.

• Fresenius Kabi Oncology reports net profit of Rs 13.19 crore in the December 2009 quarter

  Sales rise 107.78% to Rs 101.77 croreFresenius Kabi Oncology reported net profit of Rs 13.19 crore in the quarter ended December 2009 as against net loss of Rs 63.10 crore during the previous quarter ended December 2008. Sales rose 107.78% to Rs 101.77 crore in the quarter ended December 2009 as against Rs 48.98 crore during the previous quarter en...

• Fresenius Kabi Oncology's director resigns

  With effect from 13 January 2010 Fresenius Kabi Oncology has announced that John Robert Ducker, director of the company has resigned from the directorship with effect from 13 January 2010.

• Fresenius Kabi Oncology reports net profit of Rs 22.16 crore in the September 2009 quarter

  Sales rise 71.38% to Rs 99.81 croreFresenius Kabi Oncology reported net profit of Rs 22.16 crore in the quarter ended September 2009 as against net loss of Rs 33.68 crore during the previous quarter ended September 2008. Sales rose 71.38% to Rs 99.81 crore in the quarter ended September 2009 as against Rs 58.24 crore during the previous quarter end...

• Fresenius Kabi Oncology net profit declines 3.35% in the June 2009 quarter

  Net profit of Fresenius Kabi Oncology declined 3.35% to Rs 26.81 crore in the quarter ended June 2009 as against Rs 27.74 crore during the previous quarter ended June 2008. Sales rose 25.31% to Rs 97.97 crore in the quarter ended June 2009 as against Rs 78.18 crore during the previous quarter ended June 2008. ParticularsQuarter Ended Jun. 2009Jun....

• Fresenius Kabi Oncology Ltd - Dissolution of Wholly owned Subsidiary

  With reference to the earlier announcement dated February 22, 2011, Fresenius Kabi Oncology Ltd has now informed BSE that the Dabur Pharma (Thailand) Co. Ltd, the wholly owned subsidiary of Fresenius Kabi Oncology Ltd. in Thailand, has been dissolved w.e.f. January 14, 2011 as per the applicable laws in Thailand.